Hyperion DeFi, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2025, totaling $813,455, compared to $57,336 in the previous year. This growth was primarily driven by the company's digital asset operations, which generated $798,735 in revenue, marking a substantial shift from its previous focus on ophthalmological products. The company also reported a net loss of $45.3 million for the year, a slight improvement from the $49.8 million loss recorded in 2024. Hyperion's accumulated deficit now stands at approximately $240.6 million, reflecting ongoing challenges in achieving profitability.
The company has made strategic changes to its operations, including a pivot towards its Hyperliquid DeFi strategy, which emphasizes the accumulation and utilization of its native HYPE tokens. Hyperion's treasury strategy has led to the acquisition of HYPE tokens, with the company holding approximately 258 million tokens as of February 28, 2026. The Hyperliquid platform has seen significant user engagement, with over 1.1 million cumulative users and monthly trading volumes exceeding $240 billion. The company also operates a validator node on the Hyperliquid blockchain, which has contributed to its revenue through staking rewards and commission income.
Operationally, Hyperion has streamlined its workforce, reducing its employee count to nine as of December 31, 2025, following layoffs in late 2024. The company has also consolidated its research and development efforts, focusing on the Optejet ophthalmic delivery device, which is expected to be registered with the FDA in the near future. Hyperion's financial position has improved, with cash and cash equivalents increasing to $6.4 million, alongside a working capital surplus of approximately $4.5 million.
Looking ahead, Hyperion DeFi plans to continue leveraging its HYPE treasury strategy to enhance its market position and drive growth. The company is actively pursuing additional capital through its at-the-market offering program, although it acknowledges the potential challenges in securing financing on favorable terms. Hyperion's management remains focused on navigating the volatile digital asset landscape while aiming to stabilize its financial performance and expand its operational capabilities. The company is also aware of the regulatory uncertainties surrounding digital assets, which could impact its business model and market activities.
About HYPERION DEFI, INC.
Eyenovia, Inc. develops innovative ophthalmic delivery platforms, primarily the Optejet, for precise microdosing of eye medications. Its core products include FDA-approved Mydcombi for pupil dilation and licensed clobetasol propionate for post-surgical inflammation. The company focuses on improving treatment efficacy, safety, and patient compliance through targeted, low-volume delivery systems, leveraging digital health integration and strategic licensing in ophthalmology markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.